Sotac Pharmaceuticals Ltd. (SOTAC-SM) Share Price Trades Within 2% of 52-Week Low
- August 13, 2026
- Posted by: Harsh Piplani
- Category: News
Sotac Pharmaceuticals Ltd. Share Price is Rs 87.4, with the stock trading within 2% of its 52-week low. The company’s market capitalisation stands at Rs 101.6 crore.
Sotac Pharmaceuticals Ltd. Share Price stood at Rs 87.4 at the Univest screener qualification time on 13 August 2026 at 9:31:11 AM IST, placing the stock within 2% of its 52-week low. With a market capitalisation of Rs 101.6 crore, the move puts a small-cap Pharmaceuticals & Drugs stock under closer watch as traders and long-term market participants scan for signs of pressure, stabilisation or valuation support.
For Sotac Pharmaceuticals Ltd. Share Price, the immediate significance comes from context rather than a confirmed trigger. The supplied data confirms the price event, but it does not establish a company-specific catalyst behind the stock trading near its one-year bottom. That still makes the setup relevant. Stocks approaching a 52-week low often attract attention because they can reflect weak sentiment, lower risk appetite, or a market reassessment of earnings quality, balance-sheet strength and sector positioning. Univest data also shows an RSI reading of 37.54, which points to weak momentum rather than strong price strength at this stage. From here, investors tracking Sotac Pharmaceuticals Ltd. Share Price are likely to focus on whether valuation metrics, profitability data and industry comparisons offer additional perspective.
Sotac Pharmaceuticals Ltd. Share Price Today: Within 2% of 52-Week Low
| Metric | Value |
|---|---|
| LTP at 2% Qualification | Rs 87.4 |
| Market Capitalisation | Rs 101.6 crore |
| 52-Week Low Position | Trading within 2% of its 52-week low |
Sotac Pharmaceuticals Ltd. (SOTAC-SM) traded at Rs 87.4. Reported volume was 0.
Sotac Pharmaceuticals Ltd. Share Price Today is Rs 87.4, and the same Rs 87.4 level was recorded as the event-qualified last traded price by the Univest screener. The key verified development is that the stock is trading within 2% of its 52-week low, a condition that places it close to its one-year bottom without confirming any fresh breach or new low. That distinction matters because the screen identifies proximity, not a breakdown.
For investors following Sotac Pharmaceuticals Ltd. Share Price, this kind of setup often becomes a watch point because price behaviour near yearly lows can coincide with heightened scrutiny of valuation, profitability and business resilience. In smaller companies, especially in the Healthcare space, such proximity can also sharpen comparisons with similarly sized listed peers. At Rs 101.6 crore in market value, Sotac Pharmaceuticals Ltd. sits in the smaller end of the listed Pharmaceuticals & Drugs universe, which can make market sentiment shifts more visible in the share price.
The available Univest dataset confirms the price event itself but does not establish a company-specific reason behind the move. As a result, the most grounded way to read Sotac Pharmaceuticals Ltd. Share Price is through what the verified numbers already show: a stock near its 52-week low, a modest market capitalisation, and a momentum reading that is not yet strong. That naturally shifts the discussion toward technical tone and, more importantly, underlying fundamentals.
Sotac Pharmaceuticals Ltd. (SOTAC-SM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 101.6 crore |
| P/E Ratio | 17.62x |
| P/B Ratio | 1.82x |
| ROE | -85.23% |
| ROCE | -5.71% |
| EPS | Rs 5.22 |
| Book Value Per Share | Rs 50.39 |
| Dividend Yield | 0.22% |
Sotac Pharmaceuticals Ltd. was valued at a P/E ratio of 17.62x, a P/B ratio of 1.82x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of -85.23% and ROCE of -5.71%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Per-share and shareholder-return metrics included EPS of Rs 5.22, book value per share of Rs 50.39, dividend yield of 0.22%. Dividend yield is a current or historical ratio and does not guarantee future distributions.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 17.62x |
| Benchmark Median P/E | 18.99x |
| Benchmark Average P/E | 52.52x |
| Benchmark P/E Range | 0x to 3,374.81x |
| Company P/B Ratio | 1.82x |
| Benchmark Median P/B | 1.78x |
| Company ROE | -85.23% |
| Benchmark Median ROE | 10.49% |
| Company ROCE | -5.71% |
| Benchmark Median ROCE | 12.97% |
| Company Market Capitalisation | Rs 101.6 crore |
| Benchmark Median Market Cap | Rs 148.71 crore |
Sotac Pharmaceuticals Ltd. (SOTAC-SM) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Sotac Pharmaceuticals Ltd. (SOTAC-SM) has a P/E ratio of 17.62x, which is below the benchmark median of 18.99x, a difference of -7.21%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Sotac Pharmaceuticals Ltd. (SOTAC-SM) has a ROE of -85.23%, which is below the benchmark median of 10.49%, a difference of -912.49%. Sotac Pharmaceuticals Ltd. (SOTAC-SM) has a ROCE of -5.71%, which is below the benchmark median of 12.97%, a difference of -144.02%.
Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Godavari Drugs Ltd. | GODAVARI | 103.3 | 25.27 | 1.46 | 18.49 | 17.58 |
| Concord Drugs Ltd. | CONCORD | 98.69 | 47.86 | 1.96 | 13.06 | 15.69 |
| Tyche Industries Ltd. | TYCHE | 108.86 | 24.43 | 0.77 | 23.08 | 30.89 |
| Makers Laboratories Ltd. | MAKERSL | 94.44 | 27.03 | 1.19 | 20.61 | 24 |
| Mercury Laboratories Ltd. | MERCURYLAB | 94.24 | 22.64 | 1.61 | 15.5 | 20.56 |
Sotac Pharmaceuticals Ltd. (SOTAC-SM) has a P/E ratio of 17.62x compared with the displayed peer median of 25.27x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -85.23% compares with a peer median of 18.49% across the companies shown in the table. ROCE stood at -5.71% versus the displayed peer median of 20.56%, providing a capital-efficiency comparison. Sotac Pharmaceuticals Ltd. (SOTAC-SM) has a market capitalisation of Rs 101.6 crore. Among the 5 peers shown, 2 have a larger market capitalisation.
Why Investors Are Watching Sotac Pharmaceuticals Ltd.
- Sotac Pharmaceuticals Ltd. Share Price is Rs 87.4 and the stock is trading within 2% of its 52-week low, which naturally draws attention to sentiment and downside context.
- The company’s market capitalisation is Rs 101.6 crore, placing it in the smaller-cap end of the listed Pharmaceuticals & Drugs space.
- RSI at 37.54 indicates weak momentum, showing that price strength is not yet broad-based.
- Valuation multiples of 17.62 P/E and 1.82 P/B look moderate against parts of the industry, but profitability remains weak with ROE at -85.23% and ROCE at -5.71%.
- Industry benchmark data and direct peers show that return ratios lag the broader same-industry sample and several comparable listed companies.
- Univest tracking is likely to stay active because the stock combines near-52-week-low price action with mixed valuation and weak return metrics.
About Sotac Pharmaceuticals Ltd.
Sotac Pharmaceuticals Ltd. is tracked on Univest under the symbol SOTAC-SM and operates in the Healthcare sector, specifically within the Pharmaceuticals & Drugs industry. Based on the supplied classification data, the company forms part of the listed pharma universe where investors typically compare businesses through valuation ratios, profitability metrics and market-cap positioning.
At a market capitalisation of Rs 101.6 crore, Sotac Pharmaceuticals Ltd. is a relatively small listed company within its industry set. That matters because smaller pharma names can be assessed not only on earnings multiples such as P/E and asset-based measures such as P/B, but also on how effectively they generate returns on equity and capital employed. In the current market context, Sotac Pharmaceuticals Ltd. Share Price is being watched mainly through that lens as it trades close to its one-year low in the Pharmaceuticals & Drugs segment.
Track Sotac Pharmaceuticals Ltd. Share Price on Univest
Use Sotac Pharmaceuticals Ltd. (SOTAC-SM) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.
Investors who want to follow Sotac Pharmaceuticals Ltd. Share Price can track the stock on Univest for live market price updates, 52-week level monitoring, technical indicators, valuation ratios, peer comparison metrics and broader market insights. Univest also helps users review market capitalisation, profitability figures such as ROE and ROCE, book value, earnings per share and industry benchmark context in one place. For a stock trading near its yearly low, keeping all of those inputs together can make day-to-day tracking more structured and fact-based.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is Sotac Pharmaceuticals Ltd. Share Price today?
Ans. Sotac Pharmaceuticals Ltd. Share Price was Rs 87.4 at the Univest event qualification time on 13 August 2026 at 9:31:11 AM IST. The same data point also placed the stock within 2% of its 52-week low.
Why is Sotac Pharmaceuticals Ltd. Share Price attracting attention?
Ans. Sotac Pharmaceuticals Ltd. Share Price is attracting attention because Univest identified the stock trading within 2% of its 52-week low. That setup often pushes investors to compare current valuation, profitability metrics and peer positioning more closely.
What is the market capitalisation of Sotac Pharmaceuticals Ltd.?
Ans. Sotac Pharmaceuticals Ltd. has a market capitalisation of Rs 101.6 crore. That places it below the same-industry median market value of Rs 148.71 crore and well below the industry average of Rs 493.55 crore.
How do the fundamentals of Sotac Pharmaceuticals Ltd. look right now?
Ans. The current fundamental picture is mixed. Sotac Pharmaceuticals Ltd. trades at a P/E of 17.62 and P/B of 1.82, with EPS of Rs 5.22 and book value of Rs 50.39, but ROE and ROCE remain negative.
Is Sotac Pharmaceuticals Ltd. expensive compared with its industry?
Ans. On P/E, Sotac Pharmaceuticals Ltd. does not look expensive versus its same-industry benchmark. Its P/E is 17.62 compared with the median of 18.99, while its P/B of 1.82 is slightly above the median of 1.78.
How does Sotac Pharmaceuticals Ltd. compare on profitability?
Ans. Profitability is the weaker part of the comparison. Sotac Pharmaceuticals Ltd. reports ROE of -85.23% and ROCE of -5.71%, both well below the same-industry medians of 10.49% and 12.97%, respectively, in Univest benchmark data.
How does Sotac Pharmaceuticals Ltd. compare with selected listed peers?
Ans. Sotac Pharmaceuticals Ltd. is similar in size to peers such as Godavari Drugs, Concord Drugs, Tyche Industries, Makers Laboratories and Mercury Laboratories. Its P/E is lower than these peers, but its ROE and ROCE are markedly weaker.
What is the dividend yield of Sotac Pharmaceuticals Ltd.?
Ans. Sotac Pharmaceuticals Ltd. has a dividend yield of 0.22. This is a historical or current yield data point linked to the prevailing share price, and it should be viewed as context rather than a guaranteed future payout.
Where can investors track Sotac Pharmaceuticals Ltd. Share Price?
Ans. Investors can track Sotac Pharmaceuticals Ltd. Share Price on Univest for live price updates, 52-week level tracking, valuation ratios, RSI, peer metrics and industry benchmark data. That helps keep stock analysis organised around verified market information.
